Chemomab Therapeutics Ltd. American Depositary Share

Chemomab Therapeutics reported Q1 2026 financial results showing a net loss of $1.8 million and cash position of $8.0 million (runway through Q1 2027). The company presented new clinical data at major medical conferences demonstrating nebokitug's disease-modifying potential in primary sclerosing cholangitis (PSC) and potential benefits for PSC pa...

Chemomab Therapeutics reported positive 2025 results highlighted by successful FDA End-of-Phase 2 meeting for nebokitug in primary sclerosing cholangitis (PSC), establishing a clear pathway to potential regulatory approval based on a single Phase 3 trial. The company's Phase 2 SPRING trial data showed nebokitug was safe and well-tolerated with im...

Chemomab's CM-101 demonstrated anti-fibrotic, anti-inflammatory, and anti-cholestatic activity in a Phase 2 trial for primary sclerosing cholangitis, a rare liver disease. The data supports further clinical development of CM-101 for this condition.

Chemomab Therapeutics reported positive Phase 2 results for its lead drug candidate CM-101 in primary sclerosing cholangitis, demonstrating safety and anti-fibrotic, anti-inflammatory, and anti-cholestatic activity. The company plans to advance CM-101 to a Phase 3 trial and is in discussions with potential partners.

Chemomab Therapeutics, a clinical-stage biotechnology company, announced it will report its Q2 2024 financial results and provide a business update on August 21, 2024. The company is developing a monoclonal antibody, CM-101, to treat various fibro-inflammatory diseases.